Opinion|Videos|January 19, 2026
Final Thoughts on Improving Access and Care
Panelists discuss how collaboration, innovation, and stigma reduction are key to transforming schizophrenia care.
Advertisement
Episodes in this series
Panelists discuss how advancing schizophrenia care requires alignment among clinicians, policymakers, and industry to ensure consistent access to innovation.
Panelists discuss how integrating novel treatments with psychosocial support can improve adherence and empower patients toward recovery.
Panelists discuss how sustained efforts to reduce stigma and expand early intervention programs remain vital to achieving equitable, compassionate care.
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5